AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22184800 — intervention group
Group type: COMPARATOR
Intervention: Gum B (Nicotinell fruit)
Number of subjects: 607
Study 22184800 — intervention group
Group type: COMPARATOR
Intervention: Gum M (Nicotinell mint)
Number of subjects: 607
Study 22184800 — intervention group
Group type: COMPARATOR
Intervention: Gum Q (NiQuitin mint)
Number of subjects: 607
Study 19404945 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone
Number of subjects: 199
Study 19404945 — intervention group
Group type: COMPARATOR
Intervention: Single DMARD (initially sulfasalazine) with or without prednisolone
Number of subjects: 199
Study 17380844 — intervention group
Group type: EXPERIMENTAL
Intervention: lercanidipine (10 mg/day)
Number of subjects: 26
Study 17380844 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (25 mg/day)
Number of subjects: 26
Study 17278405 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing the legal obligation to report
Number of subjects: 368
Study 17278405 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing the public health benefits of reporting
Number of subjects: 368
Study 17278405 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence emphasizing both the legal obligation and public health benefits
Number of subjects: 368
Study 17278405 — intervention group
Group type: COMPARATOR
Intervention: Control group (receiving only the benefit message)
Number of subjects: 368
Study 17278405 — intervention group
Group type: COMPARATOR
Intervention: Control group (receiving only the obligation message)
Number of subjects: 368
Study 13129444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato lycopene oleoresin (30 mg/d)
Number of subjects: 75
Study 13129444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10323423 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (1 package diluted in a glass of water)
Number of subjects: 523
Study 10323423 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (2 packages diluted in 2-3 L of water)
Number of subjects: 523
Study 10323423 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna
Number of subjects: 523
Study 7592201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose breathing supine
Number of subjects: 13
Study 7592201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose breathing
Number of subjects: 13
Study 7592201 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose breathing with mouth held open
Number of subjects: 13
Study 7592201 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure application (0 to -12.5 cmH2O)
Number of subjects: 13
Study 7592201 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure via nose
Number of subjects: 13
Study 1902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with canned mackerel or herring containing long-chain n-3 fatty acids (EPA and DHA)
Number of subjects: 0
Study 1902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with canned herring (lower dose of n-3 fatty acids)
Number of subjects: 0
Study 1902298 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet supplemented with n-3 fatty acids
Number of subjects: 0
Study 6215008 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (150 mg/kg/day for urinary tract infections; 250 mg/kg/day for other infections)
Number of subjects: 107
Study 6215008 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin (200 mg/kg/day for urinary tract infections; 450 mg/kg/day for other infections)
Number of subjects: 107
Study 6215008 — intervention group
Group type: COMPARATOR
Intervention: Carbenicillin
Number of subjects: 107
Study 29727016 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed Endurance (SE)
Number of subjects: 12
Study 29727016 — intervention group
Group type: COMPARATOR
Intervention: Continuous Moderate-intensity (CM)
Number of subjects: 12
Study 29727016 — intervention group
Group type: COMPARATOR
Intervention: Repeated-Sprint (RS)
Number of subjects: 12
Study 26018112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (100 mg daily)
Number of subjects: 180
Study 26018112 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) with Vitamin C
Number of subjects: 180
Study 26018112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Vitamin C)
Number of subjects: 180
Study 25740851 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg selenium-enriched yeast
Number of subjects: 491
Study 25740851 — intervention group
Group type: EXPERIMENTAL
Intervention: 200μg selenium-enriched yeast
Number of subjects: 491
Study 25740851 — intervention group
Group type: EXPERIMENTAL
Intervention: 300μg selenium-enriched yeast
Number of subjects: 491
Study 25740851 — intervention group
Group type: COMPARATOR
Intervention: Matching yeast-based placebo tablets
Number of subjects: 491
Study 23993469 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose plus metformin fixed-dose combination (FDC)
Number of subjects: 0
Study 23993469 — intervention group
Group type: COMPARATOR
Intervention: Acarbose monotherapy
Number of subjects: 0
Study 20739581 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) suppressive therapy
Number of subjects: 0
Study 20739581 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18437288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of halphaCGRP (2 mug/min)
Number of subjects: 12
Study 18437288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16428335 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg daily
Number of subjects: 60
Study 16428335 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily
Number of subjects: 60
Study 12892157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 600 IU supplementation
Number of subjects: 20
Study 12892157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10993487 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily)
Number of subjects: 40
Study 10993487 — intervention group
Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol (700 mg daily)
Number of subjects: 40
Study 10993487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both antioxidants (Q10 and d-alpha-tocopherol)
Number of subjects: 40
Study 10993487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9176650 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacehaler with 200 micrograms salbutamol
Number of subjects: 25
Study 9176650 — intervention group
Group type: COMPARATOR
Intervention: MDI plus Volumatic spacer with 200 micrograms salbutamol
Number of subjects: 25
Study 9176650 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacehaler
Number of subjects: 25
Study 9176650 — intervention group
Group type: COMPARATOR
Intervention: MDI plus Volumatic spacer
Number of subjects: 25
Study 1288514 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam + Ranitidine (300 mg nocte)
Number of subjects: 28
Study 1288514 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam + Placebo
Number of subjects: 28
Study 3885832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 15 mg intravenously followed by 200 mg daily orally
Number of subjects: 20
Study 29090473 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 40 mg/d (DL1; n = 7)
Number of subjects: 13
Study 29090473 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib 60 mg/d (DL2; n = 6)
Number of subjects: 13
Study 29090473 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 13
Study 27515970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored improvement program including communication skills training, online patient information, and a clinical protocol for managing depressive symptoms.
Number of subjects: 1782
Study 27515970 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care).
Number of subjects: 1782
Study 27515970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored improvement program.
Number of subjects: 1782
Study 23771807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and vitamin D-fortified skimmed milk (Fe+D group, n = 55)
Number of subjects: 165
Study 23771807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified skimmed milk (Fe group, n = 54)
Number of subjects: 165
Study 23771807 — intervention group
Group type: COMPARATOR
Intervention: Usual diet without supplementation (R group, n = 56)
Number of subjects: 165
Study 23083673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus LPR and Bifidobacterium longum BL999 (LPR+BL999)
Number of subjects: 241
Study 23083673 — intervention group
Group type: EXPERIMENTAL
Intervention: L paracasei ST11 and B longum BL999 (ST11+BL999)
Number of subjects: 241
Study 23083673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 20029223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl transdermal patch (FP)
Number of subjects: 41
Study 20029223 — intervention group
Group type: COMPARATOR
Intervention: Injection of local anesthesia (IP)
Number of subjects: 41
Study 18387054 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 519
Study 18387054 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 519
Study 18387054 — intervention group
Group type: COMPARATOR
Intervention: Entecavir vs Lamivudine
Number of subjects: 519
Study 15963867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral extended-release hydromorphone (HHER) administered q24h
Number of subjects: 0
Study 15963867 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydromorphone (HHIR) dosed four times daily
Number of subjects: 0
Study 14673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)
Number of subjects: 0
Study 14673431 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs and supplements
Number of subjects: 0
Study 14673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroprotective supplements
Number of subjects: 0
Study 14673431 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscosupplementation mechanism of HA
Number of subjects: 0
Study 10545428 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CE) 0.625 mg/d
Number of subjects: 28
Study 10545428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 800 IU/d
Number of subjects: 28
Study 10545428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CE and Vitamin E
Number of subjects: 28
Study 8739514 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist 300 micrograms
Number of subjects: 29
Study 8739514 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist 600 micrograms
Number of subjects: 29
Study 8739514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study 2009118 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM 4-day group (6 h daily CPM for 4 days in hospital followed by intermittent passive motion at home)
Number of subjects: 20
Study 2009118 — intervention group
Group type: COMPARATOR
Intervention: CPM 14-day group (6 h daily CPM for 14 days)
Number of subjects: 20
Study 2009118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 6760676 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin plus ampicillin
Number of subjects: 30
Study 6760676 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin plus cephalotin
Number of subjects: 30
Study 6760676 — intervention group
Group type: COMPARATOR
Intervention: amikacin plus ampicillin and amikacin plus cephalotin
Number of subjects: 30
Study 6760676 — intervention group
Group type: COMPARATOR
Intervention: both regimens
Number of subjects: 30
Study 31053067 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Global Protocol (includes BA and PPs components)
Number of subjects: 192
Study 31053067 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based BA Protocol (without PPs component)
Number of subjects: 192
Study 31053067 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based PPs Protocol (without BA component)
Number of subjects: 192
Study 30522739 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 to 0.4 mg/kg (n = 22)
Number of subjects: 42
Study 30522739 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 42
Study 30522739 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 21)
Number of subjects: 42
Study 30522739 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain analyses
Number of subjects: 42
Study 26946057 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem high dose chemotherapy with epirubicin, cyclophosphamide, and thiotepa
Number of subjects: 143
Study 26946057 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with 2× epirubicin-cyclophosphamide followed by tandem HD chemotherapy
Number of subjects: 143
Study 26946057 — intervention group
Group type: COMPARATOR
Intervention: Dose dense chemotherapy (4× epirubicin-cyclophosphamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil)
Number of subjects: 143
Study 24057153 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 28
Study 24057153 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 28
Study 22728781 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 0
Study 22728781 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-opioid techniques
Number of subjects: 0
Study 20460174 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative complex list based randomisation solutions
Number of subjects: 0
Study 20460174 — intervention group
Group type: COMPARATOR
Intervention: Stratified randomisation
Number of subjects: 0
Study 20460174 — intervention group
Group type: COMPARATOR
Intervention: Balanced randomisation
Number of subjects: 0
Study 17506136 — intervention group
Group type: EXPERIMENTAL
Intervention: VelaSmooth system treatment on one thigh
Number of subjects: 16
Study 17506136 — intervention group
Group type: COMPARATOR
Intervention: Control thigh (untreated)
Number of subjects: 16
Study 15789316 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20
Study 15789316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15789316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Remifentanil and Placebo)
Number of subjects: 20
Study 11817917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography and photographs of atherosclerotic plaques (C group)
Number of subjects: 153
Study 11817917 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography without photographs (B group)
Number of subjects: 153
Study 11817917 — intervention group
Group type: COMPARATOR
Intervention: No ultrasonography (A group)
Number of subjects: 153
Study 11817917 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (B + C)
Number of subjects: 153
Study 11817917 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographs of plaques (C)
Number of subjects: 153
Study 10793229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral casokefamide at doses of 5.5, 8.0, and 16.0 mg
Number of subjects: 10
Study 10793229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral casokefamide
Number of subjects: 10
Study 8880681 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Physician Workstation (PWS)
Number of subjects: 37
Study 8880681 — intervention group
Group type: COMPARATOR
Intervention: Existing hospital information system (Control)
Number of subjects: 37
Study 1993412 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Timentin (3.1 g IV at commencement of operation)
Number of subjects: 271
Study 1993412 — intervention group
Group type: COMPARATOR
Intervention: Double dose of Timentin (3.1 g IV at commencement of operation and repeated after 2 hours)
Number of subjects: 271
Study 1993412 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Timentin
Number of subjects: 271
Study 1993412 — intervention group
Group type: COMPARATOR
Intervention: Double dose of Timentin
Number of subjects: 271
Study 6877579 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanji script; variations in physical size of numbers
Number of subjects: 0
Study 6877579 — intervention group
Group type: EXPERIMENTAL
Intervention: Kana script; variations in physical size of numbers
Number of subjects: 0
Study 6877579 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous performance with Kanji
Number of subjects: 0
Study 30946377 — intervention group
Group type: EXPERIMENTAL
Intervention: BiOSS LIM C stent (dedicated bifurcation balloon expandable stent made of cobalt‐chromium alloy, releasing sirolimus 1.4 μg/mm)
Number of subjects: 0
Study 30946377 — intervention group
Group type: COMPARATOR
Intervention: limus second‐generation drug‐eluting stents (DES)
Number of subjects: 0
Study 29462493 — intervention group
Group type: EXPERIMENTAL
Intervention: RT initiated >4 weeks post-op
Number of subjects: 1395
Study 29462493 — intervention group
Group type: COMPARATOR
Intervention: RT initiated ≤4 weeks post-op
Number of subjects: 1395
Study 26588232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1 and 80 mg on days 2-3)
Number of subjects: 20
Study 26588232 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant (150 mg, day 1)
Number of subjects: 20
Study 26588232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 20
Study 26588232 — intervention group
Group type: COMPARATOR
Intervention: Fosaprepitant
Number of subjects: 20
Study 24823715 — intervention group
Group type: COMPARATOR
Intervention: Saline only (group D0)
Number of subjects: 60
Study 24823715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of 1.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 0.5 μg·kg(‐1) ·h(‐1) (group D1)
Number of subjects: 60
Study 24823715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of 2.0 μg·kg(‐1) dexmedetomidine followed by a continuous infusion of 1.0 μg·kg(‐1) ·h(‐1) (group D2)
Number of subjects: 60
Study 22926161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12)
Number of subjects: 206
Study 22926161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12) in C allele carriers of MTHFR C677T variant
Number of subjects: 206
Study 22926161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B supplementation (B6, B9, B12) in A allele carriers of MTRR A66G variant
Number of subjects: 206
Study 21039835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 21039835 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 21039835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib vs Best supportive care
Number of subjects: 0
Study 17661885 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional learning (IPL) pairs
Number of subjects: 160
Study 15615740 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg)
Number of subjects: 14
Study 15615740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12087012 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. patients receiving conventional care
Number of subjects: 2849
Study 12087012 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients receiving conventional care
Number of subjects: 2849
Study 12087012 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. patients before adjustment
Number of subjects: 2849
Study 12087012 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients before adjustment
Number of subjects: 2849
Study 12087012 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. patients after adjustment for predictors
Number of subjects: 2849
Study 12087012 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients after adjustment for predictors
Number of subjects: 2849
Study 11779598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (850 mg, twice daily)
Number of subjects: 56
Study 11779598 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate induction (100 mg/day on cycle days 3‐7 of the second cycle) with Metformin
Number of subjects: 56
Study 11779598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 56
Study 11779598 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (twice daily)
Number of subjects: 56
Study 9828903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose testosterone treatment (100 mg subcutaneous implants every six months for at least two years, mean duration 3.3 ± 0.9 years)
Number of subjects: 22
Study 8016878 — intervention group
Group type: EXPERIMENTAL
Intervention: OG 37‐325 (nva‐cyclosporine, cyclosporine G)
Number of subjects: 20
Study 8016878 — intervention group
Group type: EXPERIMENTAL
Intervention: ERMBT (Erythromycin Breath Test)
Number of subjects: 20
Study 2816609 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI monotherapy (3 million units daily for 4 days, then twice weekly)
Number of subjects: 24
Study 2816609 — intervention group
Group type: COMPARATOR
Intervention: Combined HLBI with 5-FU (300 or 600 mg orally)
Number of subjects: 24
Study 2816609 — intervention group
Group type: EXPERIMENTAL
Intervention: Either HLBI treatment (monotherapy or combined)
Number of subjects: 24
Study 776840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoxan (CTX) alone
Number of subjects: 40
Study 776840 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (CTX, vincristine, and methotrexate - COM)
Number of subjects: 40
Study 6102627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clavulanic acid in combination with amoxycillin
Number of subjects: 0
Study 30761459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) application 1 month before surgery
Number of subjects: 65
Study 30761459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) application 2 weeks before surgery
Number of subjects: 65
Study 30761459 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC application)
Number of subjects: 65
Study 29530884 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564